Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $11.00.

Several research firms recently weighed in on EVAX. Weiss Ratings restated a “sell (e+)” rating on shares of Evaxion A/S in a research note on Thursday, June 11th. Wall Street Zen cut Evaxion A/S from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a report on Friday, April 24th.

Hedge Funds Weigh In On Evaxion A/S

Several large investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. purchased a new stake in Evaxion A/S during the 4th quarter valued at about $38,000. Wesbanco Bank Inc. purchased a new position in Evaxion A/S in the fourth quarter worth about $48,000. SmartHarvest Portfolios LLC purchased a new position in Evaxion A/S in the fourth quarter worth about $72,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S in the first quarter worth approximately $112,000. Finally, Renaissance Technologies LLC bought a new position in shares of Evaxion A/S in the first quarter worth approximately $146,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Trading Down 1.8%

Shares of NASDAQ EVAX opened at $3.25 on Thursday. Evaxion A/S has a 1 year low of $2.41 and a 1 year high of $12.15. The stock has a market cap of $27.11 million, a P/E ratio of -2.21 and a beta of 0.26. The firm has a 50-day moving average of $3.75 and a 200 day moving average of $3.90. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.43). As a group, sell-side analysts expect that Evaxion A/S will post -0.5 EPS for the current fiscal year.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.